Pharmaceutical high profits: the value of R&D, or oligopolistic rents?
Pharmaceutical firms attribute high prices and high profits to costs associated with researching and developing the next generation of life-saving drugs. Using data from annual reports, this article tests the validity of this claim. We find that while pharmaceutical firms do invest in R&D, they also enjoy strong rents; between 1988 and 2009, pharmaceuticals enjoyed profits of 3 to 37 times the all-industry average, depending on the years, while investing proportionately less in R&D than other high-R&D firms. Costs of pharmaceutical drugs have successfully flown below the radar in much of the current health care debate, with producers managing to obstruct alternative sourcing as well as payment cuts. While health care is examined for savings in other areas, sustained high pharmaceutical profits suggest that as a new health care policy develops in the U.S., the pharmaceutical industry should not be excluded from examination for significant savings in health care costs.
College of Saint Rose, and the CEO of Lakeview Mental Health Inc.
Janet
J
Spitz
Mark
M
Wickham
D016527:Drug Costs / Q000266:history / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000193:education / Q000266:history / Q000331:legislation & jurisprudence; D004467:Economics / Q000266:history / Q000331:legislation & jurisprudence; D017048:Health Care Costs / Q000266:history / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D049674:History, 21st Century; D004364:Pharmaceutical Preparations / Q000191:economics / Q000266:history; D012106:Research / Q000191:economics / Q000193:education / Q000266:history / Q000331:legislation & jurisprudence; D014481:United States / Q000208:ethnology
D004364:Pharmaceutical Preparations